Commission To Look Into 'Skyrocketing' EU Drug Prices, Availability, and Patient Access
Executive Summary
The European Commission, at the request of member state health ministers, is to run an analysis of the effect of incentives such as data exclusivity and supplementary protection certificates on drug prices, availability and access to medicines. Ministers have also given their backing to further voluntary cooperation initiatives among countries to rein in what they see as the very high prices of some medicines.